Related references
Note: Only part of the references are listed.Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus
Hiroyuki Tanaka et al.
ADVANCES IN THERAPY (2017)
Effect of Dapagliflozin Treatment on Fluid and Electrolyte Balance in Diabetic Rats
Ling Chen et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2016)
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes
Tim Heise et al.
CLINICAL THERAPEUTICS (2016)
Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
Hiroaki Iijima et al.
ADVANCES IN THERAPY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial
Takashi Kadowaki et al.
ADVANCES IN THERAPY (2014)
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2013)
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes
E. Ferrannini et al.
DIABETES OBESITY & METABOLISM (2013)
Vasopressin: a novel target for the prevention and retardation of kidney disease?
Lise Bankir et al.
NATURE REVIEWS NEPHROLOGY (2013)
Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus
Shigeto Kanada et al.
JOURNAL OF DIABETES INVESTIGATION (2013)
Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
Jiwen (Jim) Liu et al.
DIABETES (2012)
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
R. Grempler et al.
DIABETES OBESITY & METABOLISM (2012)